Maze Therapeutics (NASDAQ:MAZE) Upgraded to Strong-Buy at Lifesci Capital

Lifesci Capital upgraded shares of Maze Therapeutics (NASDAQ:MAZE) to a strong-buy rating in a report published on Thursday morning,Zacks.com reports.

Several other equities research analysts have also weighed in on the stock. HC Wainwright upped their target price on shares of Maze Therapeutics from $50.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, December 3rd. JPMorgan Chase & Co. boosted their price target on shares of Maze Therapeutics from $27.00 to $37.00 and gave the company an “overweight” rating in a research report on Monday, September 29th. Wall Street Zen raised shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. Weiss Ratings reiterated a “sell (d)” rating on shares of Maze Therapeutics in a research note on Wednesday, October 8th. Finally, Wedbush increased their price target on Maze Therapeutics from $35.00 to $36.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. Three equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $41.88.

Maze Therapeutics Trading Up 5.8%

MAZE stock opened at $40.62 on Thursday. Maze Therapeutics has a 1-year low of $6.71 and a 1-year high of $43.29. The business’s 50 day moving average is $34.27 and its 200-day moving average is $22.72. The firm has a market cap of $1.95 billion and a P/E ratio of -1.94.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.08.

Institutional Trading of Maze Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MAZE. Frazier Life Sciences Management L.P. acquired a new position in Maze Therapeutics during the 1st quarter valued at about $45,460,000. ARCH Venture Management LLC acquired a new stake in shares of Maze Therapeutics during the 1st quarter worth approximately $45,362,000. Matrix Capital Management Company LP bought a new stake in shares of Maze Therapeutics during the first quarter worth approximately $27,373,000. Woodline Partners LP acquired a new position in Maze Therapeutics in the first quarter valued at approximately $10,229,000. Finally, Vanguard Group Inc. boosted its stake in Maze Therapeutics by 218.1% in the third quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock valued at $34,615,000 after acquiring an additional 915,342 shares during the last quarter.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.